News & Events

News


Tuesday June 01, 2021

Neurocrine Biosciences to Present at the Goldman Sachs 42nd Annual Global Healthcare Conference

SAN DIEGO , June 1, 2021 /PRNewswire/ --  Neurocrine Biosciences, Inc. (Nasdaq: NBIX) will present at the Goldman Sachs 42 nd Annual Global Healthcare Conference at 1:20 p.m. Eastern Time on Tuesday, June 8, 2021 . Kevin Gorman , Chief Executive Officer, will present at the conference.


Tuesday May 11, 2021

Neurocrine Biosciences to Present at the 2021 RBC Global Healthcare Conference

SAN DIEGO , May 11, 2021 /PRNewswire/ --  Neurocrine Biosciences, Inc. (Nasdaq: NBIX) will present at the 2021 RBC Capital Markets Healthcare Conference at 10:55 a.m. Eastern Time on Tuesday May 18, 2021 . Matt Abernethy , Chief Financial Officer, and Eiry Roberts, Chief Medical Officer, will


Wednesday May 05, 2021

Neurocrine Biosciences Reports First Quarter 2021 Financial Results

INGREZZA® (valbenazine) First Quarter 2021 Net Product Sales of $230 Million with Approximately 43,300 TRx Initiated Pediatric Phase III Registrational Program of Crinecerfont for the Treatment of Classic Congenital Adrenal Hyperplasia Initiated Phase II Study of NBI-827104 in Essential Tremor SAN


Tuesday May 04, 2021

Neurocrine Biosciences to Present at the Bank of America 2021 Healthcare Conference

SAN DIEGO , May 4, 2021 /PRNewswire/ --  Neurocrine Biosciences, Inc. (Nasdaq: NBIX) will present at the Bank of America 2021 Healthcare Conference at 11:00 a.m. Eastern Time on Tuesday May 11, 2021 . Kevin Gorman , Chief Executive Officer, will present at the conference.


Monday May 03, 2021

Neurocrine Biosciences Supports Mental Health Month and Tardive Dyskinesia Awareness Week

- Mental Health Advocacy Community Recognizes and Over 40 States Declare First Week of May (2-8) Tardive Dyskinesia Awareness Week to Raise Awareness of this Burdensome and Often Misunderstood Condition - Recent Survey Results Show That More Than Half (60%) of People Living With Diagnosed or

Events